Ardsley Advisory Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Ardsley Advisory Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.45M	Buy	+15,000	New	+$6.65M	0.78%	43
2021 Q2	–	Sell	-70,000	Closed	-$15M	–	168
2021 Q1	$15M	Buy	+70,000	New	+$15.4M	1.83%	18
2020 Q4	–	Sell	-3,000	Closed	-$816K	–	188
2020 Q3	$816K	Hold	3,000	–	–	0.16%	75
2020 Q2	$871K	Sell	3,000 -2,000	-40%	-$542K	0.19%	62
2020 Q1	$1.19M	Buy	5,000 +2,000	+67%	+$459K	0.47%	40
2019 Q4	$657K	Sell	3,000 -2,000	-40%	-$405K	0.1%	89
2019 Q3	$847K	Hold	5,000	–	–	0.19%	69
2019 Q2	$917K	Buy	+5,000	New	+$874K	0.14%	71
2019 Q1	–	Sell	-2,000	Closed	-$331K	–	148
2018 Q4	$331K	Sell	2,000 -4,000	-67%	-$693K	0.08%	80
2018 Q3	$1.16M	Hold	6,000	–	–	0.16%	64
2018 Q2	$1.02M	Buy	6,000 +1,000	+20%	+$155K	0.15%	72
2018 Q1	$815K	Buy	5,000 +2,500	+100%	+$408K	0.12%	72
2017 Q4	$375K	Sell	2,500 -16,000	-86%	-$2.37M	0.05%	102
2017 Q3	$2.81M	Buy	+18,500	New	+$2.78M	0.37%	61
2017 Q2	–	Sell	-7,000	Closed	-$765K	–	179
2017 Q1	$765K	Buy	+7,000	New	+$616K	0.12%	84
2016 Q3	–	Sell	-2,500	Closed	-$215K	–	205
2016 Q2	$215K	Buy	+2,500	New	+$216K	0.04%	127

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Ardsley Advisory Partners's VRTX Position: Q2 2026 in Review

Ardsley Advisory Partners opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 15,000 shares worth $7.45M. The stake represents 0.78% of the portfolio and ranks #43 among its holdings. This is a return to the name: Ardsley Advisory Partners previously reported a position in VRTX as recently as Q1 2021.

Ardsley Advisory Partners first reported a position in VRTX in Q2 2016 and has held it in 16 quarters since. The position peaked at $15M in Q1 2021. 597 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Ardsley Advisory Partners held 15,000 shares of Vertex Pharmaceuticals worth $7.45M as of Q2 2026.
Vertex Pharmaceuticals was a new Ardsley Advisory Partners position in Q2 2026.
Vertex Pharmaceuticals made up 0.78% of Ardsley Advisory Partners's portfolio in Q2 2026, its #43 holding.
Ardsley Advisory Partners first reported a position in Vertex Pharmaceuticals in Q2 2016 and has held it in 16 quarters since.
Ardsley Advisory Partners's Vertex Pharmaceuticals position peaked at $15M in Q1 2021.
597 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.